Overexpression of miR-146a in basal-like breast cancer cells confers enhanced tumorigenic potential in association with altered p53 status.

The tumor suppressor p53 is the most frequently mutated gene in human cancers, mutated in 25-30% of breast cancers. However, mutation rates differ according to breast cancer subtype, being more prevalent in aggressive estrogen receptor-negative tumors and basal-like and HER2-amplified subtypes. This heterogeneity suggests that p53 may function differently across breast cancer subtypes. We used RNAi-mediated p53 knockdown (KD) and antagomir-mediated KD of microRNAs to study how gene expression and cellular response to p53 loss differ in luminal versus basal-like breast cancer. As expected, p53 loss caused downregulation of established p53 targets (e.g. p21 and miR-34 family) and increased proliferation in both luminal and basal-like cell lines. However, some p53-dependent changes were subtype specific, including expression of miR-134, miR-146a and miR-181b. To study the cellular response to miR-146a upregulation in p53-impaired basal-like lines, antagomir KD of miR-146a was performed. KD of miR-146a caused decreased proliferation and increased apoptosis, effectively ablating the effects of p53 loss. Furthermore, we found that miR-146a upregulation decreased NF-κB expression and downregulated the NF-κB-dependent extrinsic apoptotic pathway (including tumor necrosis factor, FADD and TRADD) and antagomir-mediated miR-146a KD restored expression of these components, suggesting a plausible mechanism for miR-146a-dependent cellular responses. These findings are relevant to human basal-like tumor progression in vivo, since miR-146a is highly expressed in p53 mutant basal-like breast cancers. These findings suggest that targeting miR-146a expression may have value for altering the aggressiveness of p53 mutant basal-like tumors.

[1]  J. Bergh,et al.  The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[3]  Zhongwei Cao,et al.  MicroRNA-146a acts as a metastasis suppressor in gastric cancer by targeting WASF2. , 2013, Cancer letters.

[4]  A. Børresen-Dale,et al.  TP53 and breast cancer , 2003, Human mutation.

[5]  M. Yamakuchi,et al.  miR-34a repression of SIRT1 regulates apoptosis , 2008, Proceedings of the National Academy of Sciences.

[6]  R. Lidereau,et al.  Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers , 2011, EMBO molecular medicine.

[7]  S. Schokrpur,et al.  Expression of microRNA-146 suppresses NF-κB activity with reduction of metastatic potential in breast cancer cells , 2008, Oncogene.

[8]  Hua Zhao,et al.  A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. , 2008, Carcinogenesis.

[9]  Mingming Jia,et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..

[10]  Michael A. Beer,et al.  Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. , 2007, Molecular cell.

[11]  Daya Luo,et al.  A systematic evaluation of miRNA:mRNA interactions involved in the migration and invasion of breast cancer cells , 2013, Journal of Translational Medicine.

[12]  A. Leonardi,et al.  Nuclear factor-{kappa}B contributes to anaplastic thyroid carcinomas through up-regulation of miR-146a. , 2010, The Journal of clinical endocrinology and metabolism.

[13]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  N. Perkins,et al.  Good cop, bad cop: the different faces of NF-κB , 2006, Cell Death and Differentiation.

[15]  D. Baltimore,et al.  NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses , 2006, Proceedings of the National Academy of Sciences.

[16]  N. Perkins,et al.  Good cop, bad cop: the different faces of NF-kappaB. , 2006, Cell death and differentiation.

[17]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[18]  Zhiwei Wang,et al.  miR-146a suppresses invasion of pancreatic cancer cells. , 2010, Cancer research.

[19]  Jun S. Song,et al.  Negative regulation of tumor suppressor p53 by microRNA miR-504. , 2010, Molecular cell.

[20]  C. Croce,et al.  MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. , 2009, Cancer research.

[21]  C. Gélinas,et al.  To be, or not to be: NF-κB is the answer – role of Rel/NF-κB in the regulation of apoptosis , 2003, Oncogene.

[22]  S. Le,et al.  Aberrant Expression of Oncogenic and Tumor-Suppressive MicroRNAs in Cervical Cancer Is Required for Cancer Cell Growth , 2008, PloS one.

[23]  H. Weiner,et al.  MicroRNAs are universal regulators of differentiation, activation, and polarization of microglia and macrophages in normal and diseased CNS , 2013, Glia.

[24]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[25]  S. Kato,et al.  Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations , 2005, Human mutation.

[26]  Wei Wang,et al.  MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. , 2007, Cancer research.

[27]  E. Miska,et al.  How microRNAs control cell division, differentiation and death. , 2005, Current opinion in genetics & development.

[28]  M. Espié,et al.  Distinct tumor protein p53 mutants in breast cancer subgroups , 2013, International journal of cancer.

[29]  A. Hollestelle,et al.  BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. , 2006, Cancer research.

[30]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[31]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[32]  J. Bourdon,et al.  p53 Isoforms: An Intracellular Microprocessor? , 2011, Genes & cancer.

[33]  Leonard D. Goldstein,et al.  MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype , 2007, Genome Biology.

[34]  Hiroshi I. Suzuki,et al.  Modulation of microRNA processing by p53 , 2009, Nature.

[35]  Céline Gélinas,et al.  To be, or not to be: NF-kappaB is the answer--role of Rel/NF-kappaB in the regulation of apoptosis. , 2003, Oncogene.

[36]  Hongjuan Zhao,et al.  TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer , 2007, Breast Cancer Research.

[37]  Yan Tang,et al.  Integrin-linked kinase: a hypoxia-induced anti-apoptotic factor exploited by cancer cells. , 2007, International journal of oncology.

[38]  Charles M Perou,et al.  Gene expression patterns associated with p53 status in breast cancer , 2006, BMC Cancer.

[39]  T. Byers,et al.  Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. , 2010, Cancer research.

[40]  R. Hruban,et al.  P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis , 2010, Proceedings of the National Academy of Sciences.

[41]  Jin-Wu Nam,et al.  miR-29 miRNAs activate p53 by targeting p85α and CDC42 , 2009, Nature Structural &Molecular Biology.

[42]  N. Bhattacharyya,et al.  Regulation of miR-146a by RelA/NFkB and p53 in STHdhQ111/HdhQ111 Cells, a Cell Model of Huntington's Disease , 2011, PloS one.

[43]  Joel Michalski,et al.  MicroRNA-146a modulates human bronchial epithelial cell survival in response to the cytokine-induced apoptosis. , 2009, Biochemical and biophysical research communications.

[44]  Andrea Sottoriva,et al.  The shaping and functional consequences of the microRNA landscape in breast cancer , 2013, Nature.

[45]  C. Perou,et al.  Cell-Type-Specific Responses to Chemotherapeutics in Breast Cancer , 2004, Cancer Research.

[46]  H. Lodish,et al.  MicroRNA-125b is a novel negative regulator of p53. , 2009, Genes & development.

[47]  Hailong Wu,et al.  p53 represses c-Myc through induction of the tumor suppressor miR-145 , 2009, Proceedings of the National Academy of Sciences.

[48]  R Montesano,et al.  Database of p53 gene somatic mutations in human tumors and cell lines. , 1994, Nucleic acids research.

[49]  Thierry Soussi,et al.  Assessing TP53 status in human tumours to evaluate clinical outcome , 2001, Nature Reviews Cancer.

[50]  Aimee L Jackson,et al.  Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. , 2008, Cancer research.

[51]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[52]  A. Ashkenazi,et al.  TWEAK Induces Apoptosis through a Death-signaling Complex Comprising Receptor-interacting Protein 1 (RIP1), Fas-associated Death Domain (FADD), and Caspase-8 , 2011, The Journal of Biological Chemistry.